×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SCPH – scpharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SCPH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/20
11:06 am
scph
scPharmaceuticals Inc. (NASDAQ: SCPH) had its price target lowered by analysts at Maxim Group from $20.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
scPharmaceuticals Inc. (NASDAQ: SCPH) had its price target lowered by analysts at Maxim Group from $20.00 to $12.00. They now have a "buy" rating on the stock.
3/20
08:05 am
scph
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/19
04:01 pm
scph
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/12
04:01 pm
scph
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
Low
Report
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
3/6
04:01 pm
scph
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
High
Report
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
3/5
12:00 pm
scph
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Low
Report
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
3/3
08:10 am
scph
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
2/26
04:01 pm
scph
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Low
Report
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/19
05:27 pm
scph
Form S-8 scPharmaceuticals Inc.
Low
Report
Form S-8 scPharmaceuticals Inc.
3/19
05:21 pm
scph
Form 10-K scPharmaceuticals Inc. For: Dec 31
Low
Report
Form 10-K scPharmaceuticals Inc. For: Dec 31
3/19
04:05 pm
scph
Form 8-K scPharmaceuticals Inc. For: Mar 19
Low
Report
Form 8-K scPharmaceuticals Inc. For: Mar 19
2/12
04:33 pm
scph
Form 4 scPharmaceuticals Inc. For: Feb 11 Filed by: Tucker John H
Medium
Report
Form 4 scPharmaceuticals Inc. For: Feb 11 Filed by: Tucker John H
2/12
04:27 pm
scph
Form 4 scPharmaceuticals Inc. For: Feb 11 Filed by: Nokes Rachael
Medium
Report
Form 4 scPharmaceuticals Inc. For: Feb 11 Filed by: Nokes Rachael
1/31
04:05 pm
scph
Form SCHEDULE 13G/A scPharmaceuticals Inc. Filed by: HIRSCHMAN ORIN
Medium
Report
Form SCHEDULE 13G/A scPharmaceuticals Inc. Filed by: HIRSCHMAN ORIN
1/28
10:57 am
scph
Form SCHEDULE 13G/A scPharmaceuticals Inc. Filed by: KING LUTHER CAPITAL MANAGEMENT CORP
Low
Report
Form SCHEDULE 13G/A scPharmaceuticals Inc. Filed by: KING LUTHER CAPITAL MANAGEMENT CORP
1/10
08:02 am
scph
Form 8-K scPharmaceuticals Inc. For: Jan 10
Medium
Report
Form 8-K scPharmaceuticals Inc. For: Jan 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Q4/2019 12/31/2019 EPS -0.270 ZacksConsensus -0.540 ActVsEst 0.270 - Beat
40.7%
8/7 Q2/2019 6/30/2019 EPS -0.390 ZacksConsensus N/A ActVsEst N/A - N/A 16.9%
2/19 Form 4 scPharmaceuticals Inc. For: Feb 14 Filed by: Kolchinsky Peter 14.0%
3/24 Form S-8 scPharmaceuticals Inc. 11.0%
10/31 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.0%
12/12 scPharmaceuticals Inc. Announces Recent Progress on FUROSCIX® and Highlights Corporate Objectives 6.8%
8/15 scPharmaceuticals (SCPH) Presents At Wedbush PacGrow Healthcare Conference - Slideshow [Seeking Alpha] 5.8%
12/21 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%
5/8 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus -0.590 ActVsEst 0.120 - Beat 4.8%
8/10 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 4.4%
8/7 Q2/2019 6/30/2019 EPS -0.390 ZacksConsensus N/A ActVsEst N/A - N/A 16.9%
2/19 Form 4 scPharmaceuticals Inc. For: Feb 14 Filed by: Kolchinsky Peter 14.0%
3/24 Form S-8 scPharmaceuticals Inc. 11.0%
10/31 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.0%
12/12 scPharmaceuticals Inc. Announces Recent Progress on FUROSCIX® and Highlights Corporate Objectives 6.8%
8/15 scPharmaceuticals (SCPH) Presents At Wedbush PacGrow Healthcare Conference - Slideshow [Seeking Alpha] 5.8%
12/21 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%
5/8 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus -0.590 ActVsEst 0.120 - Beat 4.8%
8/10 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 4.4%
TOP News Decliners
11/14
scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference
-11.5%
6/20 Form 4 scPharmaceuticals Inc. For: Jun 18 Filed by: VEITINGER KLAUS R DR -10.1%
12/14 Scpharmaceuticals Inc (NASDAQ: SCPH) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%
11/14 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.5%
11/12 Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.430 ActVsEst 0.100 - Beat -6.9%
8/7 Form 10-Q scPharmaceuticals Inc. For: Jun 30 -5.8%
8/23 Form 424B5 scPharmaceuticals Inc. -5.7%
1/11 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -5.3%
5/30 scPharmaceuticals Inc. to Present at Upcoming Investor Conferences -5.2%
11/26 scPharmaceuticals Inc. to Present at the Piper Jaffray 31st Annual Healthcare Conference -5.2%
6/20 Form 4 scPharmaceuticals Inc. For: Jun 18 Filed by: VEITINGER KLAUS R DR -10.1%
12/14 Scpharmaceuticals Inc (NASDAQ: SCPH) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%
11/14 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.5%
11/12 Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.430 ActVsEst 0.100 - Beat -6.9%
8/7 Form 10-Q scPharmaceuticals Inc. For: Jun 30 -5.8%
8/23 Form 424B5 scPharmaceuticals Inc. -5.7%
1/11 Scpharmaceuticals Inc (NASDAQ: SCPH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -5.3%
5/30 scPharmaceuticals Inc. to Present at Upcoming Investor Conferences -5.2%
11/26 scPharmaceuticals Inc. to Present at the Piper Jaffray 31st Annual Healthcare Conference -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: